Research progress in effects of proton pump inhibitors on Coronavirus Disease 2019

YI Chunfang

doi:10.7619/jcmp.20213234

Journal of Clinical Medicine in Practice > 2021 > 25(23): 110-114. > DOI: 10.7619/jcmp.20213234

YI Chunfang. Research progress in effects of proton pump inhibitors on Coronavirus Disease 2019[J]. Journal of Clinical Medicine in Practice, 2021, 25(23): 110-114. DOI: 10.7619/jcmp.20213234

Citation:

YI Chunfang. Research progress in effects of proton pump inhibitors on Coronavirus Disease 2019[J]. Journal of Clinical Medicine in Practice, 2021, 25(23): 110-114. DOI: 10.7619/jcmp.20213234

Citation:

YI Chunfang. Research progress in effects of proton pump inhibitors on Coronavirus Disease 2019[J]. Journal of Clinical Medicine in Practice, 2021, 25(23): 110-114. DOI: 10.7619/jcmp.20213234

PDF (640 KB)

Research progress in effects of proton pump inhibitors on Coronavirus Disease 2019

YI Chunfang

Department of Pharmacy,Affiliated Hospital of Liaoning University of Traditional Chinese Medicine,Shenyang,Liaoning,110032

More Information

Received Date: August 10, 2021
Available Online: December 20, 2021
Published Date: December 14, 2021

Graphical Abstract

Abstract

Abstract

The infection mechanism of novel coronavirus infection involves a two-step process where the spike glycoprotein first binds to a cell surface receptor and is subsequently cleaved by a cellular protease to facilitate membrane fusion.Proton pump inhibitors (PPIs) can inhibit the spread of novel coronarirus in many ways.It inhibits cavitation proton pump to lead to raised organelle pH sorts and transports complex by targeting endosome inhibits membrane fusion and replication of novel coronavirus infection,and prevents viral transmission from infected to uninfected cells.They also can act against novel coronavirus infection by exerting anti-inflammatory and antifibrotic effects so as to reduce the clinical symptoms of pneumonia.Combined drug therapy can also be used to enhance the antiviral properties of other drugs.But the current clinical evidences do not point towards a beneficial effect clearly yet.This paper reviewed the potential therapeutic effects and clinical risks of PPIs on Coronavirus Disease 2019(COVID-19) based on the existing evidences,aiming to make clinical attention to the balance between the risks and benefiting associated with COVID-19 and PPIs.
- proton pump inhibitors,
- Coronavirus Disease 2019,
- therapy,
- risk of infection,
- severity

FullText(HTML)

References (48)

References

[1]	MINALYAN A,GABRIELYAN L,SCOTT D,et al.The gastric and intestinal microbiome: role of proton pump inhibitors[J].Curr Gastroenterol Rep,2017,19(8): 42. doi: 10.1007/s11894-017-0577-6
[2]	KAUR G,KAUR M,SILAKARI O.Benzimidazoles: an ideal privileged drug scaffold for the design of multitargeted anti-inflammatory ligands[J].Mini Rev Med Chem,2014,14(9): 747-767. doi: 10.2174/1389557514666140820120518
[3]	KONDAPURAM S K,SARVAGALLA S,COUMAR M S.Targeting autophagy with small molecules for cancer therapy[J].J Cancer Metastasis Treat,2019,5(4): 32. http://qikan.cqvip.com/Qikan/Article/Detail?id=00004HKCK53F0EGJNX8G7JP167DO5JP1MBR
[4]	HOMOLAK J,KODVANJ I.Widely available lysosome targeting agents should be considered as potential therapy for COVID-19[J].Int J Antimicrob Agents,2020,56(2): 106044. doi: 10.1016/j.ijantimicag.2020.106044
[5]	LU R,ZHAO X,LI J,et al.Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding[J].Lancet,2020,395(10224): 565-574. doi: 10.1016/S0140-6736(20)30251-8
[6]	HOFFMANN M,KLEINE-WEBER H,SCHROEDER S,et al.SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor[J].Cell,2020,181(2): 271-280.e8. doi: 10.1016/j.cell.2020.02.052
[7]	WRAPP D,WANG N,CORBETT K S,et al.Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation[J].Science,2020,367(6483): 1260-1263. doi: 10.1126/science.abb2507
[8]	DE MILITO A,IESSI E,LOGOZZI M,et al.Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species[J].Cancer Res,2007,67(11): 5408-5417. doi: 10.1158/0008-5472.CAN-06-4095
[9]	BELOUZARD S,MILLET J K,LICITRA B N,et al.Mechanisms of coronavirus cell entry mediated by the viral spike protein[J].Viruses,2012,4(6): 1011-1033. doi: 10.3390/v4061011
[10]	MAZZON M,MARSH M.Targeting viral entry as a strategy for broad-spectrum antivirals[J].F1000Res,2019,8: 1628. doi: 10.12688/f1000research.19694.1
[11]	FALLAHZADEH M K,BORHANI HAGHIGHI A,NAMAZI M R.Proton pump inhibitors: predisposers to Alzheimer disease[J].J Clin Pharm Ther,2010,35(2): 125-126. doi: 10.1111/j.1365-2710.2009.01100.x
[12]	ARAGÃO D S,CUNHA T S,ARITA D Y,et al.Purification and characterization of angiotensin converting enzyme 2 (ACE2) from murine model of mesangial cell in culture[J].Int J Biol Macromol,2011,49(1): 79-84. doi: 10.1016/j.ijbiomac.2011.03.018
[13]	LIU J,JI H,ZHENG W,et al.Sex differences in renal angiotensin converting enzyme 2 (ACE2) activity are 17β-oestradiol-dependent and sex chromosome-independent[J].Biol Sex Differ,2010,1(1): 6. doi: 10.1186/2042-6410-1-6
[14]	CONRAD K P.Might proton pump or sodium-hydrogen exchanger inhibitors be of value to ameliorate SARs-CoV-2 pathophysiology[J].Physiol Rep,2021,8(24): e14649. doi: 10.14814/phy2.14649
[15]	MOORE P S,GAO S J,DOMINGUEZ G,et al.Primary characterization of a herpesvirus agent associated with Kaposi′s sarcomae[J].J Virol,1996,70(1): 549-558. doi: 10.1128/jvi.70.1.549-558.1996
[16]	MARSHANSKY V,FUTAI M.The V-type H⁺-ATPase in vesicular trafficking: targeting,regulation and function[J].Curr Opin Cell Biol,2008,20(4): 415-426. doi: 10.1016/j.ceb.2008.03.015
[17]	TOURET F,GILLES M,BARRAL K,et al.In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication[J].Sci Rep,2020,10(1): 13093. doi: 10.1038/s41598-020-70143-6
[18]	WANG H,YANG P,LIU K,et al.SARS coronavirus entry into host cells through a novel clathrin-and caveolae-independent endocytic pathway[J].Cell Res,2008,18(2): 290-301. doi: 10.1038/cr.2008.15
[19]	SOBHY H.A review of functional motifs utilized by viruses[J].Proteomes,2016,4(1): 3. doi: 10.3390/proteomes4010003
[20]	WATANABE S M,EHRLICH L S,STRICKLAND M,et al.Selective targeting of virus replication by proton pump inhibitors[J].Sci Rep,2020,10(1): 4003. doi: 10.1038/s41598-020-60544-y
[21]	TABATA K,ARIMOTO M,ARAKAWA M,et al.Unique requirement for ESCRT factors in Flavivirus particle formation on the endoplasmic Reticulum[J].Cell Rep,2016,16(9): 2339-2347. doi: 10.1016/j.celrep.2016.07.068
[22]	IRIE T,LICATA J M,MCGETTIGAN J P,et al.Budding of PP_xY-containing rhabdoviruses is not dependent on host proteins TGS101 and VPS4A[J].J Virol,2004,78(6): 2657-2665. doi: 10.1128/JVI.78.6.2657-2665.2004
[23]	TAN M,LIU Y,ZHOU R,et al.Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou,China[J].Immunology,2020,160(3): 261-268. doi: 10.1111/imm.13223
[24]	ZHANG B,ZHOU X,ZHU C,et al.Immune phenotyping based on the neutrophil-to-lymphocyte ratio and IgG level predicts disease severity and outcome for patients with COVID-19[J].Front Mol Biosci,2020,7: 157. doi: 10.3389/fmolb.2020.00157
[25]	CAO X.COVID-19: immunopathology and its implications for therapy[J].Nat Rev Immunol,2020,20(5): 269-270. doi: 10.1038/s41577-020-0308-3
[26]	SASAKI T,NAKAYAMA K,YASUDA H,et al.A new strategy with proton pump inhibitors for the prevention of acute exacerbations in COPD[J].Ther Adv Respir Dis,2011,5(2): 91-103. doi: 10.1177/1753465810392264
[27]	BECKER J C,GROSSER N,WALTKE C,et al.Beyond gastric acid reduction: proton pump inhibitors induce heme oxygenase-1 in gastric and endothelial cells[J].Biochem Biophys Res Commun,2006,345(3): 1014-1021. doi: 10.1016/j.bbrc.2006.04.170
[28]	OHARA T,ARAKAWA T.Lansoprazole decreases peripheral blood monocytes and intercellular adhesion molecule-1-positive mononuclear cells[J].Dig Dis Sci,1999,44(8): 1710-1715. doi: 10.1023/A:1026604203237
[29]	KOUNTOURAS J,BOURA P,LYGIDAKIS N J.Omeprazole and regulation of cytokine profile in Helicobacter pylori-infected patients with duodenal ulcer disease[J].Hepatogastroenterology,2000,47(35): 1301-1304. http://www.ncbi.nlm.nih.gov/pubmed/11100337
[30]	WANDALL J H.Effects of omeprazole on neutrophil chemotaxis,super oxide production,degranulation,and translocation of cytochrome b-245[J].Gut,1992,33(5): 617-621. doi: 10.1136/gut.33.5.617
[31]	UBAGAI T,KOSHIBU Y,KOSHIO O,et al.Downregulation of immunomodulator gene expression in LPS-stimulated human polymorphonuclear leukocytes by the proton pump inhibitor lansoprazole[J].J Infect Chemother,2009,15(6): 374-379. doi: 10.1007/s10156-009-0728-2
[32]	BIÇAKÇI U,TANDER B,ARITVRK E,et al.Effects of omeprazole and gentamicin on the biochemical and histopathological alterations of the hypoxia/reoxygenation induced intestinal injury in newborn rats[J].Pediatr Surg Int,2005,21(10): 800-805. doi: 10.1007/s00383-005-1538-y
[33]	ZUO W,ZHAO X,CHEN Y.SARS coronavirus and lung fibrosis[J].Molecular Biology of the SARS-Coronavirus,2009: 247-258.
[34]	YE Q,DALAVANGA Y,POULAKIS N,et al.Decreased expression of haem oxygenase-1 by alveolar macrophages in idiopathic pulmonary fibrosis[J].Eur Respir J,2008,31(5): 1030-1036. doi: 10.1183/09031936.00125407
[35]	HAMMOND C L,ROZTOCIL E,PHIPPS R P,et al.Proton pump inhibitors attenuate myofibroblast formation associated with thyroid eye disease through the aryl hydrocarbon receptor[J].PLoS One,2019,14(9): e0222779. doi: 10.1371/journal.pone.0222779
[36]	GHEBRE Y T.Proton pump inhibitors in IPF: a call for clinical trials[J].Front Pharmacol,2018,9: 499. doi: 10.3389/fphar.2018.00499
[37]	CHEN M,LU J,WEI W,et al.Effects of proton pump inhibitors on reversing multidrug resistance via downregulating V-ATPases/PI3K/Akt/mTOR/HIF-1α signaling pathway through TSC1/2 complex and Rheb in human gastric adenocarcinoma cells in vitro and in vivo[J].Onco Targets Ther,2018,11: 6705-6722. doi: 10.2147/OTT.S161198
[38]	BOJKOVA D,MCGREIG J E,MCLAUGHLIN K M,et al.SARS-CoV-2 and SARS-CoV differ in their cell tropism and drug sensitivity profiles[J].BioRxiv,2020,[Epub ahead of print].
[39]	BLANC F,WAECHTER C,VOGEL T,et al.Interest of proton pump inhibitors in reducing the occurrence of COVID-19: A case-control study[J].Preprints,2020,[Epub ahead of print].
[40]	ALMARIO C V,CHEY W D,SPIEGEL B M R.Increased risk of COVID-19 among users of proton pump inhibitors[J].Am J Gastroenterol,2020,115(10): 1707-1715. doi: 10.14309/ajg.0000000000000798
[41]	LUXENBURGER H,STURM L,BIEVER P,et al.Treatment with proton pump inhibitors increases the risk of secondary infections and ARDS in hospitalized patients with COVID-19: coincidence or underestimated risk factor[J].J Intern Med,2021,289(1): 121-124. doi: 10.1111/joim.13121
[42]	LEE S W,HA E K,YENIOVA A Ö,et al.Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching[J].Gut,2021,70(1): 76-84. doi: 10.1136/gutjnl-2020-322248
[43]	ZHOU J D,WANG X S,LEE S,et al.Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score-matched territory-wide study[J].Gut,2021,70(10): 2012-2013. doi: 10.1136/gutjnl-2020-323668
[44]	RAMACHANDRAN P,PERISETTI A,GAJENDRAN M,et al.Pre-hospitalization proton pump inhibitor use and clinical outcomes in COVID-19[J].Eur J Gastroenterol Hepatol,2020,[Epub ahead of print].
[45]	HARIYANTO T I,PRASETYA I B,KURNIAWAN A.Proton pump inhibitor use is associated with increased risk of severity and mortality from coronavirus disease 2019 (COVID-19) infection[J].Dig Liver Dis,2020,52(12): 1410-1412. doi: 10.1016/j.dld.2020.10.001
[46]	ZHANG X Y,LI T,WU H,et al.Analysis of the effect of proton-pump inhibitors on the course of COVID-19[J].J Inflamm Res,2021,14: 287-298. doi: 10.2147/JIR.S292303
[47]	BALOUCH B,VONTELA S,YEAKEL H,et al.Role of Famotidine and Other Acid Reflux Medications for SARS-CoV-2: A Pilot Study[J].J Voice,2021,[Epub ahead of print].
[48]	ISRAELSEN S B,ERNST M T,LUNDH A,et al.Proton pump inhibitor use is not strongly associated with SARS-CoV-2 related outcomes: a nationwide study and meta-analysis[J].Clin Gastroenterol Hepatol,2021,19(9): 1845-1854.e6. doi: 10.1016/j.cgh.2021.05.011

[1]	LI Ruibiao, REN Chengbo, WANG Cong, LI Yaru. Comparison of the efficacy of dosimetric parameters defined by different lung volume methods in predicting radiation pneumonitis in patients with non-small cell lung cancer[J]. Journal of Clinical Medicine in Practice, 2022, 26(19): 5-8, 13. DOI: 10.7619/jcmp.20221246
[2]	ZHOU Hui, SHAN Shucan. Dosimetry and passing rate of forward-intensity modulated radiation therapy and intensity modulated radiation therapy for left breast cancer patients with breast conserving surgery[J]. Journal of Clinical Medicine in Practice, 2021, 25(1): 15-18. DOI: 10.7619/jcmp.20200319
[3]	PAN Xiang, YANG Yi, HOU Yu, YUAN Meifang. Dosimetric differences of different radiation modes based on Monaco in postoperative intensity modulated radiotherapy of patients with left breast-conserving surgery for breast cancer[J]. Journal of Clinical Medicine in Practice, 2021, 25(1): 1-5. DOI: 10.7619/jcmp.20200621
[4]	YUAN Meifang, ZHAO Biao, YANG Yi, TANG Kewei, AN Yijun. Static intensity-modulated radiotherapy versus volumetric modulated arc therapy in dosimetric parameters of target area and organs at risk for middle thoracic esophageal cancer[J]. Journal of Clinical Medicine in Practice, 2020, 24(15): 21-24. DOI: 10.7619/jcmp.202015006
[5]	PAN Xiang, LI Ya, ZHU Sijin, YANG Yi. Dosimetry difference between field-in-field intensity modulated radiation therapy and fixed field inversely optimized intensity modulated radiation therapy in whole brain radiotherapy[J]. Journal of Clinical Medicine in Practice, 2019, 23(19): 12-16. DOI: 10.7619/jcmp.201919003
[6]	LU Yuting, WANG Jian, LIN Tao, SUI Jianfeng, YU Jingping, NI Xinye, SUN Suping. Dosimetry comparison between two different supraclavicular areas irradiation schedules for post-operation breast cancer and its influence on life quality[J]. Journal of Clinical Medicine in Practice, 2016, (19): 34-36. DOI: 10.7619/jcmp.201619010
[7]	LIU Wanjun, ZHANG Xizhi, LI Jun, HUA Wei, ZHANG Xianwen, CHEN Xuemei. Effects of dose calculation algorithm on dosiology of breast cancer patients with intensity modulated radiation therapy[J]. Journal of Clinical Medicine in Practice, 2016, (15): 28-32. DOI: 10.7619/jcmp.201615008
[8]	SONG Chengxia, WANG Jing. Dosimetric study of volumetric modulated arc therapy and intensity modulated radiation therapy in postoperative radiotherapy of cervical carcinoma[J]. Journal of Clinical Medicine in Practice, 2015, (23): 75-77,81. DOI: 10.7619/jcmp.201523023
[9]	LI Jinkai, CAO Yuandong, LI Caihong, WANG Peipei, SUN Xinchen. Application of volumetric modulated radiation therapy in the radiotherapy of patients with left breast cancer after breast-conserving surgery[J]. Journal of Clinical Medicine in Practice, 2015, (21): 59-62. DOI: 10.7619/jcmp.201521016
[10]	LI Danming, WANG Li, SUN Xinchen, MU Qingxia, PEI Zhongling. Dosimetric comparison between two volumetric modulated photon arc therapies for patients with breast cancer mastecomy[J]. Journal of Clinical Medicine in Practice, 2014, (16): 70-74. DOI: 10.7619/jcmp.201416020

Cited By

Cited by

Periodical cited type(2)

1.	黄梦钰，王雅梅. 非编码RNA在口腔鳞状细胞癌耐药机制中的研究进展. 医学研究杂志. 2024(05): 22-26 .
2.	王军成，兰彦平，赵岳阳，蒯涛，马东明，李敏. LINK-A RNAi慢病毒载体构建及其抑制U251胶质瘤细胞增殖的研究. 宁夏医学杂志. 2023(07): 577-580+572 .

Other cited types(0)

Get Citation

PDF

XML

Article views (295) PDF downloads (27) Cited by(2)

Turn off MathJax

Article Contents

Abstract

References

Research progress in effects of proton pump inhibitors on Coronavirus Disease 2019

Abstract

References

Related Articles

Cited by

Periodical cited type(2)

Other cited types(0)

Catalog

Research progress in effects of proton pump inhibitors on Coronavirus Disease 2019

Abstract

References

Related Articles

Cited by

Periodical cited type(2)

Other cited types(0)

Catalog

Export File

Citation

Format

Content